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Crystal Jaing7, Nicholas A Be7, Eric Elster5,8 and Paul A Luciw1,2Abstract
Background: The ability to forecast whether a wound will heal after closure without further debridement(s), would
provide substantial benefits to patients with severe extremity trauma.
Methods: Wound effluent is a readily available material which can be collected without disturbing healthy tissue.
For analysis of potential host response biomarkers, forty four serial combat wound effluent samples from 19
patients with either healing or failing traumatic- and other combat-related wounds were examined by 2-D DIGE.
Spot map patterns were correlated to eventual wound outcome (healed or wound failure) and analyzed using
DeCyder 7.0 and differential proteins identified via LC-MS/MS.
Results: This approach identified 52 protein spots that were differentially expressed and thus represent candidate
biomarkers for this clinical application. Many of these proteins are intimately involved in inflammatory and immune
responses. Furthermore, discriminate analysis further refined the 52 differential protein spots to a smaller subset of
which successfully differentiate between wounds that will heal and those that will fail and require further surgical
intervention with greater than 83% accuracy.
Conclusion: These results suggest candidates for a panel of protein biomarkers that may aid traumatic wound care
prognosis and treatment. We recommend that this strategy be refined, and then externally validated, in future
studies of traumatic wounds.
Keywords: Traumatic wound, Proteomics, 2-D DIGE, Wound effluent, Biomarker discovery, Wound dehiscenceIntroduction
The combination of effective body armor and the use of
improvised explosion devices in modern warfare have
greatly increased the incidence of severe survivable trau-
matic injuries [1-4]. Comprising approximately half of
all current combat wounds, this mechanism of injury
predominately affects the extremities and devastates
skin, musculoskeletal tissue, the neurovascular system,
and bone [4-7]. Several factors can contribute to the
ability of a wound to heal or to dehisce, including the
extent of injury, time from wound occurrence to care,
individual immune and inflammatory responses, and mi-
crobial colonization. However, no widely used prognostic
assay quantitatively predicts whether a traumatic wound
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reproduction in any medium, provided the orFailure of the healing process of chronic wounds in-
curs massive health care costs, totaling up to $3 billion
per year [8]. In general, the healing of wounds is a tightly
regulated process involving hemostasis, inflammation,
cell proliferation, and tissue remodeling. Wounds with
impaired healing do not progress through these normal
stages due to many factors including local wound char-
acteristics, such as, oxygenation, microbial presence, and
venous supply [9]. The inflammation phase is critical for
the removal of contaminating organisms and, if removal
is not sufficient, the remaining bacteria and endotoxins
can lead to a prolonged inflammatory response [10].
One of the most commonly cited wound outcome indi-
cators is the extent of microbial presence [5], which is
clinically binned into one of three categories: contamin-
ation (non-replicating organisms present), colonization
(replicating organisms present) and local infection/crit-
ical colonization (intermediate stage with local tissuel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient demographics and clinical characteristics
Patient Demographics and Clinical Characteristics Healed Dehisced
n = 21 n = 23
Age, y 23.7 ± 3.8 22 ± 3.2
BMI, mean (SD) 26 ± 2.4 25 ± 3.8
Gender, n (%)
Male 21 (100%) 23 (100%)
Female 0 (0%) 0 (0%)
Wound Location, n
Upper Body 19 0
Lower Body 2 23
Wound Type, n
Soft Tissue Infection 12 17
Fasciotomy 5 7
Amputation 3 0
Open Fracture 1 0





Injury Severity Score, mean (SD) 20 ± 8.3 17 ± 7.3
No. of Total Surgeries, mean (SD) 3.8 ± 1.2 3.6 ± 1.4




Presence of Heterotrophic Ossification, n
Yes 16 21
No 5 2
Days from Injury to Arrival at Facility, mean (SD) 4.2 ± 1.6 4.4 ± 1.4
Days from Injury to Wound Closure, mean (SD) 12.1 ± 3.8 11.7 ± 4.9
Days from Injury to Sample Collection, mean (SD) 6.2 ± 1.4 6.6 ± 1.5
Days from Sample Collection to Closure, mean (SD) 5.9 ± 3.8 5.0 ± 4.5
The demographic and clinical characteristics of the 20 patients that comprised
the 44 wound effluent samples are displayed.
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ated with wound outcome, current clinical microbiology
is not sufficient to predict non-healing, therefore, alter-
native methods need to be explored.
Current research on wound outcome focuses on cor-
relating changes in levels of certain host proteins, in-
cluding chemokines, cytokines, metalloproteinases and
other proteases, and inflammatory marker proteins;
these studies indicate that poor combat wound healing
is associated with dysregulation of the inflammatory re-
sponse [5,11-13]. In this report, we expand upon previ-
ous effort by describing a comprehensive study that aims
to analyze the wound effluent proteome and provide a
preliminary biomarker panel of proteins that can differ-
entiate between uneventful healing and wound failure
(such as dehiscence, failure of graft or flap, removal of
biologic matrix) after surgical closure. If successful, these
discriminating proteins can be further developed for use
as a prognostic tool to aid physicians in predicting
wound outcome and thus providing optimal care for
traumatic- and otherwise combat-related injuries.
Materials and methods
Patients and sample collection
The study methodology is as reported elsewhere [5,11]
and is reiterated here for completeness. In brief, serial
samples were collected in an observational study with
prospective data collection in accordance with the insti-
tutional review board of the Walter Reed National Mili-
tary Medical Center (Bethesda, MD). All service
members evacuated to the National Capital Area from
Iraq and Afghanistan that had sustained high-energy
penetrating injuries to one or more extremities and were
without confounding co-morbid conditions, such as im-
mune disorders, connective tissue disorders, or any con-
ditions requiring immunosuppressive agents, were
eligible for inclusion. Surgical debridement, lavage, and
negative-pressure wound therapy (NPWT) were re-
peated every 48–72 hours until surgical wound closure
or coverage at the discretion of the attending surgeon
and in accordance with current institutional standards of
practice. Patients were followed throughout their recov-
ery for a minimum of six weeks to determine whether
their wounds healed normally or dehisced (Table 1).
Wound effluent samples (≥30 ml) were collected from
the NPWT canister (without gel pack; Kinetic Concepts,
Inc., San Antonio, TX) over a 12-hour period prior to
each wound debridement and 2 hours following the first
surgical debridement and subsequent surgical debride-
ments. The samples used in this study were collected
from up to three wounds for up to three serial debride-
ments. Samples were treated like serum and centrifuged
at 2500 x g for 10 minutes to remove particulate matter
and emboli. Effluent supernatants were transferred toindividually labeled polypropylene tubes, flash-frozen in
liquid nitrogen, and stored at −80°C until analysis.
Removal of highly abundant proteins
Depletion of high abundant proteins was performed ac-
cording to manufacturer’s instructions. Briefly, patient
wound effluent was diluted five fold in Buffer A (Agilent
Technologies) into 200 μl total volume and centrifuged
through a 0.22 micron spin filter (Millipore) tube at
16,000 x g for 5 min to remove particulates. Then efflu-
ent fluids were processed using Multiple Affinity Re-
moval Column Human-6 (Agilent Technologies), which
specifically removes albumin, IgA, IgG, antitrypsin,
transferrin and haptoglobin. A low abundant protein
fraction was collected for each sample. Fractions were
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20% trichloroacetic acid solution and incubated at 4°C
for 30 min. The precipitate was washed twice with cold
100% acetone, allowed to air dry, and then resuspended
in DIGE labeling buffer (7 M urea, 2 M thiourea, 4%
CHAPS, 30 mM Tris, pH 8.5). Protein quantification
was performed using Precision Red Advanced Protein
Assay Reagent (Cytoskeleton Inc.).
2-D DIGE analysis
Crude and high abundant protein depleted effluent sam-
ples were separated in 2 dimensions according to GE
Life Sciences Ettan DIGE system protocol. Briefly, each
sample (50 μg) was minimally labeled with 200 pmol
Cy3 or Cy5 for 30 min, a pooled standard of all 44 ex-
perimental samples were labeled similarly with Cy2. All
labeling reactions were stopped by the addition of 1 μl
of 1 mM lysine. Individually labeled samples were
pooled and added to rehydration buffer (7 M urea, 2 M
thiourea, 4% CHAPS, 1.2% destreak, 1% pharmalytes). A
final volume of 450 μl sample was loaded onto
24 cm pH3-10NL Immobiline DryStrips (GE Life Sci-
ences) and focused by active overnight rehydration,
followed by active isoelectric focusing for a total of
62,500 Vhrs. Strips were equilibrated in SDS equilibra-
tion buffer (6 M urea, 30% glycerol, 2% SDS) for 15 min
with 10 mg/ml DTT, then 15 min in fresh buffer with
25 mg/ml 15 min with iodoacetamide, then applied to
DIGE gels (GE Life Sciences) for 2nd dimension separ-
ation. The resulting CyDye labeled protein gels were
scanned using 100 micron resolution on Typhoon 9410
(GE Life Sciences).
DeCyder multivariate analysis
Data analysis was carried out using the various modules
of DeCyder 2-D 7.0 software (GE Life Sciences). The dif-
ference in-gel analysis (DIA) module was used to deter-
mine the optimal and average spot detection settings.
All 22 gel images were given to the batch processor
module with the designated settings to generate spot
maps using 2,500 as the estimated number of spots. Cy2
labeled pooled standard was used to normalize spot in-
tensity within each gel. The spot map with the greatest
number of detected spots was set as the master gel, and
biological variation analysis (BVA) module was then used
for automated spot matching across all the gels. Gel
matching quality was manually verified, and landmarks
were added where improved matching quality was needed.
The extended data analysis (EDA) software package (GE
Life Sciences) was used for differential protein determin-
ation, PCA, hierarchical clustering, k-means partitioning
analysis and discriminate analysis calculations [14].
For identification of differential proteins, each sample
spot map was assembled into the appropriate experimentalgroup (healed or dehisced wounds), and the average ratio
fold-change were calculated. A base set was established
using only spots that were matched on greater than 60% of
the spot maps. Spots having fold change > 1.2 and p-value
< 0.05 (according to [15]) were considered differentially
expressed, each spot was manually verified for an accept-
able three dimensional characteristic protein profile and for
adequate material for subsequent mass spectrometry identi-
fication. Spots not meeting these criteria were excluded
from further analysis. The set of confirmed differential
proteins for each of the experimental group comparisons
was used for PCA, hierarchical clustering (heat map and
k-means calculations) and discriminate analysis.
Protein digestion and identification
Differential proteins were excised from a preparative gel
with additional protein for identification purposes. Ex-
cised gel pieces were destained in 100 mM ammonium
bicarbonate for 1 h at room temperature, dehydrated
with successive 100% acetonitrile washes and dried in a
SpeedVac for 30 min. The gel pieces were then rehy-
drated with 130 ng modified porcine trypsin (Promega)
in 50 mM ammonium bicarbonate and incubated for
16 h at 37°C. Supernatants were collected and peptides
further extracted with 5% trifluoroacetic acid in 50%
acetonitrile, supernatants and extraction fluid were
pooled together. Tryptic peptides were concentrated
down to 5 μl by SpeedVac and analyzed by a LC-MS/MS
LTQ-Orbitrap using nanoflow HPLC with a HALO C18
reversed phase separation column (Bruker-Michrom).
The resulting peak lists were searched against the Hu-
man International Protein Index database using the
MASCOT search engine according to the following pa-
rameters: up to two missed cleavages, peptide mass tol-
erance of 1.2 Da, fragment mass tolerance of 0.6 Da,
fixed modification carbamidation, and variable modifica-
tion oxidation (M). Protein identifications with probabil-
ity score of 95% or higher and contain at least two
unique peptides were considered valid.
Functional classification
A list of UniProt IDs for the 45 identified differential
spots among healed versus dehisced wounds were sub-
mitted to the GORetriever online tool to retrieve their
GO annotations. Corresponding GO annotations and
online plugin tool CateGOrizer were used to categorize
the proteins according to Immune System Gene class
classification list, producing a pie chart to display the
distribution of involved functions.
Results
In this study, we characterized the proteome of trau-
matic wound patient effluent samples (n = 44). Effluent
was collected at the Naval Medical Research Center
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earlier wound closure.
All effluent samples were subjected to removal of high
abundant proteins to improve overall spot clarity and
separated by 2-D DIGE according to protocols estab-
lished by Chromy et al. [16]. Spot maps were analyzed
by DeCyder 7.0 by which a total of 1800 spots were de-
tected and quantified in each the 22 gels using the DIA
module, and gel-to-gel spot matching was performed
using the BVA module. This approach yielded a signifi-
cant increase in the number of discernible protein spots
when compared to a similar analysis of crude wound ef-
fluent, which lead to increased sensitivity and opportun-
ity to find novel protein biomarkers.
Differential protein spot determination
Differential protein spots were matched on greater than
60% of the spot maps, had a fold change > 1.2 [15] with
a p-value < 0.05. A total of 52 unique protein spots were
determined to be differential; their distribution on theFigure 1 Differential expression analysis. A total of 52 unique protein sp
boundary is defined in orange and labeled with assigned spot number. Dif
mass spectrometry.preparative pick gel is shown in Figure 1. The 52 differ-
ential spots were excised and 45 spots were confidently
identified yielding 25 unique proteins. Assigned spot
number, IPI database number, gene/protein name, MAS-
COT score, fold change/t-test along with theoretical mo-
lecular weight and pI are displayed for each identified
protein in Table 2. Many areas on the gel show several
spots in a horizontal line and were determined to be the
same protein with slight variations in their pI [17]. Be-
cause only some of the spots in the line were determined
to be differential, these data indicate that post-
translational modifications of specific proteins are im-
portant in discriminating between healed and dehisced
effluent samples.
PCA and hierarchical clustering
The 52 verified differential proteins were used for PCA
of the wound effluent sample spot maps. Figure 2A
shows good separation between healed and dehisced
samples, supporting the theory that the host proteomeots with greater than 1.2 fold change and p-value < 0.05. Each spot
ferential spots were excised from the gel and identified via
Table 2 Proteins showing differential responses






T-test Th. MW Th. pI
59 IPI00440484 PER1 Period Circadian protein homolog 1 133 −1.23 0.0414 137667 5.73
95* IPI00645206 PCDH17 Isoform 1 of Protocadherin 17 131 −1.22 0.0121 127405 5.03
99* IPI00235407 STK36 Isoform 1 of Serine/threonine protein kinase 3 142 −1.24 0.0018 145728 5.57
102 IPI00185661 USP32 Ubiquitin carboxyl terminal hydrolase 32 125 −1.2 0.0164 145671 6.18
106 IPI00470744 PARG Isoform 2 of Poly (ADP-ribose) glycohydrolase 113 −1.22 0.0106 103503 5.58
168* IPI00290328 PTPRJ Receptor type tyrosine protein phosphotase precursor 130 −1.51 0.0061 152960 5.8
195* IPI00017601 CP Ceruloplasmin 101 −1.27 0.0116 122983 5.44
198* IPI00017601 CP Ceruloplasmin 121 −1.39 0.0076 122983 5.44
199 IPI00017601 CP Ceruloplasmin 182 −1.31 0.0095 122983 5.44
200 IPI00017601 CP Ceruloplasmin 116 −1.33 0.0075 122983 5.44
201 IPI00017601 CP Ceruloplasmin 112 −1.3 0.0254 122983 5.44
202 IPI00017601 CP Ceruloplasmin 154 −1.31 0.0130 122983 5.44
329 IPI00011736 PIK3R2 Phosphatidylinositol 3 kinase regulatory subunit 2 88 1.26 0.0259 81837 6.03
330 IPI00783987 C3 Complement C3 115 1.55 0.0003 188569 6.02
333 IPI00011736 PIK3R2 Phosphatidylinositol 3 kinase regulatory subunit 2 111 1.25 0.0046 81837 6.03
337 IPI00783987 C3 Complement C3 88 1.53 0.0104 188569 6.02
341* IPI00783987 C3 Complement C3 147 1.56 0.0006 188569 6.02
343* IPI00783987 C3 Complement C3 189 1.62 0.0006 188569 6.02
344 IPI00783987 C3 Complement C3 120 1.69 0.0048 188569 6.02
345 IPI00783987 C3 Complement C3 79 1.59 0.0125 188569 6.02
347 IPI00783987 C3 Complement C3 104 1.52 0.0339 188569 6.02
375* IPI00607814 XPNPEP1 Xaa-Pro aminopeptidase 1 Isoform 2 121 1.23 0.0415 72746 5.67
389 IPI00157535 EPS8L1 Isoform 4 of Epigrowth factor receptor kinase subunit 8 118 1.23 0.0168 88920 6.49
436 IPI00009089 FRS3 Fibroblast growth factor receptor substrate 3 121 −1.28 0.0198 55169 6.81
582 IPI00301255 IGSF21 Immunoglobulin superfamily member 21 109 −1.23 0.0480 51855 6.48
602 IPI00329555 F7 Isoform A of Coagulation factor VII 178 −1.54 0.0232 53043 6.91
607 IPI00329555 F7 Isoform A of Coagulation factor VII 130 −1.37 0.0462 53043 6.91
787 IPI00021891 FGG Fibrinogen gamma chain 1 135 1.33 0.0267 51511 5.37
794 IPI00847635 SERPINA3 Isoform 1 of alpha-1-antichymotrypsin 146 1.57 0.0067 47792 5.33
800 IPI00847635 SERPINA3 Isoform 1 of alpha-1-antichymotrypsin 216 1.22 0.0273 47792 5.33
814 IPI00219330 ILF3 Isoform 5 of Interleukin enhancer binding factor 3 252 −1.35 0.0205 74959 8.4
869 IPI00783625 SERPINB5 Isoform 1 of Serpin B5 120 1.27 0.0356 42530 5.72
872* IPI00847635 SERPINA3 Isoform 1 of alpha-1-antichymotrypsin 111 1.39 0.0456 47792 5.33
876 IPI00847635 SERPINA3 Isoform 1 of alpha-1-antichymotrypsin 283 1.24 0.0424 47792 5.33
976 IPI00004657 HLA-B HLA class 1 histocompatibility antigen 102 1.27 0.0150 40777 5.57
980 IPI00004657 HLA-B HLA class 1 histocompatibility antigen 121 1.34 0.0383 40777 5.57
981 IPI00004657 HLA-B HLA class 1 histocompatibility antigen 101 1.57 0.0008 40777 5.57
1080 IPI00166729 AZGP1 Zinc alpha 2 glycoprotein precursor 147 −1.34 0.0031 34258 5.71
1177 IPI00555812 GC Vitamin D binding protein precursor 104 −1.28 0.0151 52963 5.4
1186 IPI00641737 HP Haptoglobin 92 −1.29 0.0374 45205 6.13
1374 IPI00978715 CLU Clusterin 109 −1.25 0.0106 52495 5.88
1381 IPI00410313 KIR3KL3 Killer cell immunoglobulin like receptor 3DL3 132 1.25 0.0144 45470 7.27
1392 IPI00022391 APCS Serum Amyloid P component 181 1.48 0.0223 25837 6.1
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1487 IPI00386246 AMPH Amphiphysin I variant CT3, fragment 119 1.24 0.0251 31195 4.23
1796 IPI00007879 SRF Serum response factor 132 1.21 0.0460 51592 7.83
The 45 identified differential spots found among biological replicates of healed versus dehisced wounds (corresponding to t-test < 0.05 and fold change cutoff >
1.2) were identified via LC-MS/MS and yieled 25 unique protein identifications. The table includes spot number, IPI database number, gene name, protein name,
MASCOT identification score, fold change and t-test of expression between healed and dehisced wounds, theoretical molecular weight and pI. *Indicates the 9
proteins selected as markers by discriminate analysis. Spot numbers 332, 336, 548, 763, 978, and 1797 were unable to be confidently identified.
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outcome. Figure 2B shows hierarchical clustering of the
differential proteins, using the average abundance of
each spot within each experimental group. Figure 2C
was produced by cluster analysis using the 52 differential
spots; the spot maps showing similar protein expression
patterns are clustered together. Similar to the PCA re-
sult, hierarchical clustering adequately separated healed
spot maps from dehisced spot maps.
K-means protein clusters and functions
K-means partitioning analysis, within the DeCyder EDA
module, exposes protein spot clusters exhibiting similar
expression patterns (Figure 3). Interestingly, many of
these proteins regulate different aspects of immunity
and inflammatory responses. Specifically, cluster 1 is
comprised of 5 (spot no. 337, 343, 344, 345, 347) of 12
separate spots with nearly identical molecular weights
and slightly shifted pI values, encompassing the left half
of the horizontal spot streak. All spots were identified as
complement C3 protein and are individually, as well as
collectively, upregulated in dehisced wound effluent
samples. This acidic pI shift is commonly caused by post
translational modifications (PTMs) [18], such as phos-
phorylation, which is a key regulatory mechanism in
most systemic responses [19] that alters activation state
of proteins [17]. In particular, phosphorylation has been
shown to activate complement C3 by increasing comple-
ment binding [20] and opsonization [21] of invading
pathogens, and is involved in anti-inflammatory regula-
tory mechanisms [22]. These data suggest that not only
the overall protein expression level is important, but the
abundance of certain isoforms that are a result of spe-
cific PTMs can help discriminate between healed and
dehisced wound effluent.
The set of 25 unique differential proteins were func-
tionally categorized using CateGOrizer according to the
Immune System gene classes classification list (Figure 4).
The largest functional class is metabolism, which is con-
sistent with a large number of proteins having some in-
volvement in cellular metabolism. The second largest
category is stress response, which relates to the systemic
impact of a major wound on the patient. These data
strongly suggest that host proteins involved in respond-
ing to stress are changing abundance according to
wound outcome. Moreover, these results are consistentwith previous studies showing the importance of the
stress response in wound healing [23-26].
Discriminate analysis
Patterns of differentially expressed proteins were ana-
lyzed via the EDA module to determine the appropriate
biomarker panel that effectively discriminates between
healed and dehisced wound effluent (Table 3). Panel A
displays the 9 selected protein biomarkers with the re-
spective discrimination accuracy (83.83% ± 2.8) and
Panel B lists their gene names and protein identifica-
tions. These markers include protocadherin 17, serine/
threonine protein kinase 3, receptor type tyrosine pro-
tein phosphotase precursor, ceruloplasmin (2 spots),
complement C3 (2 spots), xaa-pro aminopeptidase 1,
and alpha-1-antichymotrypsin. Most importantly, these
proteins could be used in a biomarker panel to deter-
mine which sample a particular host proteome belongs
to and be further developed for use in a prognostic pro-
tein panel to aid physicians in selecting appropriate trau-
matic wound trauma treatment. Thus, 2-D DIGE data
have revealed a set of protein biomarkers which can ef-
fectively discriminate between healed and dehisced
wound effluent samples.
Discussion
Initial treatment of traumatic- and other combat-related
injuries involves aggressive resuscitation measures in
conjunction with debridement procedures that are
geared towards achieving hemostasis and the removal of
devitalized tissue. Wounds are treated with negative
pressure wound therapy, and left open for subsequent
serial debridement procedures. This is necessary because
the zone of injury in traumatic- and other high-energy
wounds may not be obvious at the outset, and evolves
over time. As such, timing of definitive closure is largely
subjective, as the surgeon weighs the benefits of success-
ful wound closure, with the risk of wound failure which
will necessitate further, perhaps more aggressive, de-
bridement procedures, and can ultimately jeopardize
fracture fixation and/or current levels of amputation. In
addition, treatment of failed wounds prolongs the hos-
pital length of stay and delays rehabilitation, resulting in
an increase of healthcare costs to both the payer and pa-
tient. The main cause for this subjective decision is the
lack of techniques that can objectively assess the
Figure 2 DeCyder cluster analysis. Fifty two verified differential expression protein spots (t-test > 0.5, fold change > 1.2) were used for the
following analyses using DeCyder Extended Data Analysis. (A) Principle component analysis shows good separation between healed and
dehisced samples; each dot represents an individual gel spot map. (B) Hierarchical clustering using the average abundance of differential spots
for each experimental group, experimental groups are displayed in columns and protein spots by row, differential expression is displayed by color
(red being up-regulated and green being down-regulated relative to the pooled standard. Clusters of differential proteins showing similar expres-
sion patterns are further defined in Figure 4. (C) Hierarchical clustering of 44 spot maps according to the 52 differential protein spots, individual
patient spot maps are displayed by column and protein spots by rows.
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tend successful wound healing [27].
Wound effluent (exudate) has proven to be a rich
source of protein biomarkers that are associated with
wound healing outcome in other types of extremity
wounds. Two research groups have used a similar gel
electrophoresis-based technique, one dimensional SDS-PAGE followed by band excision and LC-MS/MS pro-
tein identification, to analyze the proteome of wound ef-
fluent. Eming et al. [28] analyzed patient effluent from
healing and nonhealing venous leg ulcer wounds and
identified 149 differentially expressed proteins. Many of
these proteins are known to be involved in persistent in-
flammatory or tissue destruction responses which allow
Figure 3 K-means partitioning analysis. Five clusters of proteins spots with similar expression patterns. Spot abundance, identification and
known functional category are displayed to expose biological processes involved in distinguishing between healed and dehiscing wounds.
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type of wound. Escalante et al. [29] analyzed the prote-
ome of effluent collected from mice injected with 2 dif-
ferent types of snake venom enzymes. Their results
showed a total of 78 differentially expressed proteins (10
serum proteins, 34 cytosolic proteins, 16 keratins, 2
macroglobulins, and 16 extracellular matrix proteins)
which provided novel information on the tissue dam-
aging pathogenic mechanisms of these toxins and the
subsequently triggered inflammatory reaction. Takentogether, these studies provide evidence that wound ef-
fluent directly reflects the wound site microenvironment
and is, therefore, a suitable candidate for identifying pro-
tein biomarkers that can discriminate between various
stages of healing.
Other studies have used gel-based proteomics to
examine wound effluent from chronic wounds. For ex-
ample, Upton and coworkers, applying the same affinity
chromatography used in this manuscript, found that re-
moval of high abundant proteins enhanced the ability to
Figure 4 Functional classifications. The list of 45 identified differential proteins were functionally categorized into classes according to the
Immune System Gene classification list using the CateGOrizer online tool.
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[30]. The same group produced a review article on the
state of proteomics in chronic wound research and sug-
gested affinity chromatography can also be beneficial to
compensate for dynamic range problems normally asso-
ciated with gel-based proteomics. A further suggestion
to increase the dynamic range of 2D gels is to use im-
proved pI separations. This review also suggested that
using methods such as 2-D DIGE could compensate for
the variable protein amounts and small clinical samples
available for wound research [31]. Herein, we use these
gel proteomic enhancements, namely, 2-D DIGE with
large format gels that increase the pI separation and af-
finity chromatography to improve the dynamic range of
the studied proteome. Other important literature show-
ing proteomic characterization of chronic wound fluidTable 3 Discriminate analysis
A. Comparison (left vs. right) Differential P
Healed Dehisced 52
B. Healed vs. Dehisced Discriminate Markers
Spot No. Gene Name Protein Name
95 PCH17 Protocadherin
99 STK36 Serine/threoni





375 XPNPEP1 Xaa-Pro amino
872 SERPINA3 Alpha-1-antich
Differential proteins were used to determine the appropriate marker selection panel of
samples. A total of 9 markers were selected which give greater than 83% accuracy (pacomes from Wyffels and coworkers, who published two
articles using different techniques (one using gels, the
other using MS and protein arrays) [32,33]. Their earlier
manuscript shows proteomic differences between the in-
terior and periphery of wounds using 2DE. They also
found differences between chronic and healed wounds,
identifying S100A9 as a putative biomarker of wound
healing. They report that 2DE is not optimal for the
characterization of the protein profile of chronic wounds
and alternate techniques, mass spectrometry and protein
arrays, which they used in the more recent publication are
needed. The use of multiple proteomic techniques for full
characterization is optimal and taken together, the two pa-
pers from Wyfells and coworkers show a comprehensive
approach to proteomic characterization with the use of
the three main proteomic characterization techniques:roteins Markers selected Accuracy (%)
9 83.83 ± 2.8
17
ne protein kinase 3





proteins that effectively discriminate between healed and dehisced effluent
nel A), the corresponding protein identifications are shown in panel B.
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itional techniques for comprehensive proteomic charac-
terization, however, an important distinction exists
between the gel-based work in the 2010 Wyfells manu-
script and ours. We use 2-D DIGE as compared to con-
ventional 2DE. The 2-D DIGE approach uses an internal
pooled standard that removes the major problem with gel-
based proteomics, namely the gel to gel variation. In
addition, the use of the 2-D DIGE system allows for lower
level detection and increases the potential pool of putative
biomarkers. Nonetheless, this literature from chronic
wound fluid proteomics helps guide our future work,
which will include additional proteomic techniques for
more comprehensive characterization.
Current biomarker research from our group, involving
traumatic and other high-energy combat wounds, is
based on the analysis of serum, effluent and tissue bi-
opsy specimens [11-13]. This work led to a unique un-
derstanding of the mechanisms involved in healing with
regards to the timing of surgical wound closure. Many
proinflammatory proteins and cytokines show increased
expression in dehiscing wounds: procalcitonin [12] and
IL-6 [11] (serum and effluent); IL-8 [11] (serum and tis-
sue biopsy); MMP-2, MMP-3, MMP-7 [13], CCL3 [11]
(serum only); IL-1 alpha/beta, CCL2, and GM-CSF [11]
(tissue biopsy only). Similarly, other inflammatory medi-
ator proteins display decreased expression in wounds
that failed to heal: IL-13 (effluent [12] and tissue biopsy
[11]); CCL5 [12], IL-2, inducible protein-10 [11] (effluent
only); IL-4, IL-5 [11] (tissue biopsy only). The bio-
markers found in this current study will be used along
with these other ongoing cytokine-based immunoassay
results to further the development of assays that can
characterize wounds and lead to improved prognostic
tools. We aim to use these prognostic tools to aid physi-
cians in predicting wound outcome and provide optimal
care for traumatic- and other combat-related injuries.
In this study, the classes of proteins that make up the
highest percent of change include those involved with
metabolism, stress, and cell death (Figure 4). These re-
sults are not surprising as wound healing requires sub-
stantial changes in cell growth, cell maintenance, and
cell death to be completed successfully. Over 40% of the
proteins that are differentially expressed involve metab-
olism, while almost 20% are involved in stress, and an-
other 13+% involve apoptosis. The emphasis of
differential expression on these protein classes suggests
that specific pathways that lead to cell growth, autoph-
agy, and cell death are vital for appropriate wound heal-
ing. Moreover, the pattern of protein expression,
especially given sufficient redundancy for certain cell
functions, may also help to characterize appropriate
wound healing. Future characterization of protein ex-
pression changes with additional diverse datasets maylead to functional models that can characterize new
wounds and help determine their treatment route lead-
ing to appropriate healing.
Dysfunction and dysregulation of inflammatory and
immune responses as a contributing factor to determin-
ing wound outcome support the result of this wound ef-
fluent proteomic profiling study of combat wound
effluent. Of the 52 differential proteins, complement C3
(C3), alpha-1-antichymotrypsin (SERPINA3), immuno-
globulin superfamily member 21 (IGSF21), HLA class 1
histocompatability antigen (HLA-B), clusterin (CLU),
haptoglobin (HP), serum amyloid P component (APCS)
have roles in immune and/or inflammatory responses
and were found to be differentially expressed between
healed and dehisced wound effluent samples. In
addition, two proteins involved in hemostasis showed
differential expression, i.e. decrease of coagulation factor
VII (F7) and increase of fibrinogen gamma chain (FGG)
in dehisced samples.
Most importantly, the discriminate marker panel
(Table 3) displays the 9 protein spots that can differenti-
ate an effluent sample as healed or dehisced with an ac-
curacy of greater than 83%. Accordingly, these proteins
have the potential to be developed into a prognostic
panel which can be used by physicians to determine a
wound’s likeliness to heal normally or dehisce after sur-
gical closure. Evaluating wound effluent from traumatic-
and other combat wounds using the advanced proteomic
method of 2-D DIGE is an important step to under-
standing the protein expression changes in the local
wound environment.
Conclusions
This research contributes to our development of a per-
sonalized clinical treatment of combat wounds which
will help mitigate the risk of wound closure in this chal-
lenging clinical scenario, and potentially lead to im-
proved healing outcomes while decreasing the number
of surgical procedures, hospital length of stay and costs.
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